| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H24N2 |
| Molecular Weight | 316.4394 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CC1=C2C=CC=CC2=NC(=C1)C3=CC=CC=C3)C4CCNCC4
InChI
InChIKey=AMEWZCMTSIONOX-UHFFFAOYSA-N
InChI=1S/C22H24N2/c1-2-6-18(7-3-1)22-16-19(11-10-17-12-14-23-15-13-17)20-8-4-5-9-21(20)24-22/h1-9,16-17,23H,10-15H2
| Molecular Formula | C22H24N2 |
| Molecular Weight | 316.4394 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 197.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
healthy volunteers: 50 - 150 mg. administration route is not specified.
Route of Administration:
Unknown
In vitro studies of rat cuneate nucleus indicated that the proconvulsant actions of PK 8165 could be explained by its direct, albeit slightly different, interactions with the GABA-receptor complex. PK 8165 (100 microM) alone had no effect on responses to the GABA analogue muscimol, but enhanced the potency of picrotoxin as an antagonist of muscimol and reduced the potency of flurazepam as a potentiator of muscimol.
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
